BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31859887)

  • 1. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma.
    Kustic D; Lovasic F; Belac-Lovasic I; Avirovic M; Ruzic A; Petretic-Majnaric S
    Rev Med Chil; 2019 May; 147(5):557-567. PubMed ID: 31859887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
    Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.
    Plaza MJ; Handa P; Esserman LE
    AJR Am J Roentgenol; 2017 Apr; 208(4):910-915. PubMed ID: 28140614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study.
    Narbe U; Bendahl PO; Fernö M; Ingvar C; Dihge L; Rydén L
    Br J Surg; 2021 Dec; 108(12):1465-1473. PubMed ID: 34636842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of extranodal extension in axillary lymph node-positive breast cancer.
    Ma X; Yang X; Yang W; Shui R
    Sci Rep; 2021 May; 11(1):9534. PubMed ID: 33953240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.
    Peg V; Sansano I; Vieites B; Bernet L; Cano R; Córdoba A; Sancho M; Martín MD; Vilardell F; Cazorla A; Espinosa-Bravo M; Pérez-García JM; Cortés J; Rubio IT; Ramón Y Cajal S
    Breast; 2017 Jun; 33():8-13. PubMed ID: 28254641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
    Barron AU; Hoskin TL; Boughey JC
    Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sentinel node tumor burden on outcome of invasive breast cancer patients.
    Meattini I; Desideri I; Saieva C; Francolini G; Scotti V; Bonomo P; Greto D; Mangoni M; Nori J; Orzalesi L; Fambrini M; Bianchi S; Livi L
    Eur J Surg Oncol; 2014 Oct; 40(10):1195-202. PubMed ID: 25179162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
    Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Lobbezoo DJ; Tjan-Heijnen VC; Voogd AC
    Clin Breast Cancer; 2016 Aug; 16(4):e75-82. PubMed ID: 27116948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
    Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
    Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.